相关实验视频
Updated: Jun 29, 2025

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.0K
通过改善HFD养小鼠的胰岛素信号通路,LRP1促进肝脏糖生成
Xingxian Guo1, Jiangxia Pu1, Ziqi Tang1
1Centre for Lipid Research & Chongqing Key Laboratory of Metabolism on Lipid and Glucose, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Animal models and experimental medicine
|April 3, 2024
概括
与LDL受体相关的蛋白-1 (LRP1) 通过改善胰岛素信号传递来促进肝糖生成. 它的β链对于这一过程至关重要,为肝脏的胰岛素抵抗提供了潜在的治疗点.
科学领域:
- 代谢过程中的代谢.
- 细胞生物学 细胞生物学
- 内分泌学 在内分泌学.
背景情况:
- 与LDL受体相关的蛋白-1 (LRP1) 是一个细胞表面受体,参与各种生理过程.
- 之前的研究表明,肝细胞特异性LRP1缺陷 (hLRP1KO) 会加剧胰岛素抵抗和肝脏葡萄糖生成.
- 在肝糖生成中LRP1的作用仍未确定.
研究的目的:
- 调查LRP1在调节肝糖生成中的作用.
- 阐明LRP1的β链对这一过程的特定贡献.
- 探索LRP1作为肝脏胰岛素耐药性的潜在治疗点.
主要方法:
- 评估胰岛素信号传递,糖原基因表达和hLRP1KO小鼠和HepG2细胞中的糖原含量.
- 在体外和体外使用pcDNA 3.1等离子体和AAV8载体对截断的LRP1β链 (β∆) 过度表达.
- 在HepG2细胞中通过palmitate调节LRP1表达的分析.
主要成果:
- 在正常的食中,hLRP1KO小鼠表现出胰岛素信号受损和肝脏糖原含量降低.
- 帕尔米抑制了HepG2细胞中的LRP1表达,抑制了胰岛素刺激的糖原合成.
- 过度表达LRP1的β∆链在体外和体内恢复了胰岛素信号传递,并增强了肝脏糖生成和糖原储存,特别是在高脂肪饮食养的小鼠中.
结论:
- LRP1,特别是它的β链,在促进肝脏葡萄糖生成方面发挥着关键作用.
- 通过改善胰岛素信号通路,LRP1可以增强肝脏糖生成.
- LRP1调节为与肝脏胰岛素抵抗相关的疾病提供了一种新的治疗策略.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K

